September 17, 2014 — A new clinical trial found that vascular closure devices (VCDs) are non-inferior to manual compression in patients undergoing transfemoral coronary angiography. The findings were reported at the 2014 Transcatheter Cardiovascular Therapeutics (TCT) annual scientific sessions in Washington, D.C.

September 17, 2014 — GE Healthcare announced it has installed its Cath Lab Efficiency Manager at Saint Luke’s Mid America Heart Institute in Kansas City, Mo. The solution is a new analytical tool that analyzes the performance of an interventional lab, providing hospitals with important data they can use to identify areas of improvement.

Unexpected trips to the hospital are inconvenient and worrisome for anyone, but for congestive heart failure sufferers, they can be all too frequent.

BioControl Medical announced that it has reached an important clinical trial milestone, reaching 480 randomized subjects — or 70 percent — of the planned 650 subjects with congestive heart failure (HF) in the INOVATE-HF (INcrease Of VAgal TonE in Heart Failure) trial of its CardioFit system, the first medical device designed to treat HF using neurostimulation.

September 16, 2014 — A quarter of adults in the United States have two or more chronic medical conditions, as do more than two-thirds of seniors, yet there are few clinical practice guidelines for cardiologists that take such comorbid conditions and their treatment into consideration.

September 16, 2014 — Advanced Accelerator Applications (AAA), an international specialist in molecular nuclear medicine, announced this week it has entered into an agreement with GE Healthcare in Italy to acquire its Italian FDG-PET imaging agent business (fluorodeoxyglucose positron emission tomography). This acquisition includes the license to market GE Healthcare’s SteriPET (FDG) imaging agent in Italy.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now